After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival– Based on totality of data, iTeos and GSK have agreed to terminate the ...

All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial is ending. GSK is communicating with investigators, institutional review boards, ...

About Belrestotug (EOS-448/GSK4428859A) Belrestotug is an Fc active human immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T cell immunoglobulin and immunoreceptor tyrosine-based ...

It said the collaboration and all belrestotug-containing study cohorts are ending as a result. The drug was being developed as a potential treatment for various cancers.

GSK halts belrestotug program after trial setbacksShould you invest $2,000 in GSK right now? Before you buy stock in GSK, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by ...

LONDON - GSK plc (LSE/NYSE:LON:GSK), in collaboration with iTeos Therapeutics, Inc., announced today the termination of their joint development program for belrestotug, an investigational anti-TIGIT ...

GSK provides update on belrestotug development programme GSK plc (LSE/NYSE: GSK), with its development partner iTeos Therapeutics, Inc., has confirmed it is ending the development programme for ...

All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial is ending.